Characterization of myeloproliferative neoplasms in the paediatric and young adult population

Compared with older patients with MPNs, pediatric and young adult patients (PAYA) with MPNs demonstrated longer survival from diagnosis (median not reached vs. 13 years; log rank P < 0.001) and less frequent disease transformation (19.3% vs. 37.9%; P < 0.001), according to data from a study of genomic features and clinical outcomes among the two age groups. Venous thrombosis was more common among the PAYA group compared with the older patient group (19.8% vs. 10.7%; P = 0.002). The older group had a higher presence of JAK2 somatic mutation (80.4% vs. 64.3%; P < 0.001), while the PAYA group more commonly had CALR mutation (20.5% vs. 10.5%, P = 0.001) or lack of any traditional driver mutation (8.8% vs. 3.7%; P = 0.01).